Russell Investments Group Ltd. Boosts Holdings in Cencora, Inc. (NYSE:COR)

Russell Investments Group Ltd. boosted its position in shares of Cencora, Inc. (NYSE:COR) by 22.7% during the 4th quarter, HoldingsChannel.com reports. The firm owned 220,517 shares of the company’s stock after purchasing an additional 40,751 shares during the period. Russell Investments Group Ltd.’s holdings in Cencora were worth $49,546,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Boston Partners grew its holdings in shares of Cencora by 2.6% during the fourth quarter. Boston Partners now owns 5,007,100 shares of the company’s stock valued at $1,128,058,000 after buying an additional 125,611 shares during the last quarter. Geode Capital Management LLC lifted its position in Cencora by 3.1% in the 4th quarter. Geode Capital Management LLC now owns 4,326,064 shares of the company’s stock valued at $969,471,000 after acquiring an additional 130,213 shares in the last quarter. Pacer Advisors Inc. boosted its stake in Cencora by 6.7% during the 4th quarter. Pacer Advisors Inc. now owns 2,204,242 shares of the company’s stock valued at $495,249,000 after purchasing an additional 138,868 shares during the last quarter. Norges Bank bought a new stake in shares of Cencora in the 4th quarter worth $478,309,000. Finally, Raymond James Financial Inc. purchased a new position in shares of Cencora in the fourth quarter worth $322,460,000. 97.52% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently commented on COR. Wells Fargo & Company increased their price objective on Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a research report on Friday, March 14th. JPMorgan Chase & Co. boosted their price objective on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a report on Friday, January 24th. StockNews.com upgraded shares of Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday, March 12th. Finally, Evercore ISI lifted their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, Cencora has a consensus rating of “Moderate Buy” and a consensus target price of $280.20.

Insider Buying and Selling at Cencora

In other news, EVP Elizabeth S. Campbell sold 4,127 shares of the stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the completion of the transaction, the executive vice president now directly owns 14,665 shares in the company, valued at approximately $3,934,326.20. This represents a 21.96 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Steven H. Collis sold 14,578 shares of the business’s stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $269.51, for a total transaction of $3,928,916.78. Following the completion of the sale, the chairman now owns 317,913 shares in the company, valued at $85,680,732.63. This represents a 4.38 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,675 shares of company stock valued at $8,034,778 over the last ninety days. 10.80% of the stock is currently owned by company insiders.

Cencora Stock Down 3.5 %

COR stock opened at $279.29 on Monday. The business’s 50-day moving average price is $257.28 and its 200-day moving average price is $242.81. The stock has a market cap of $54.16 billion, a P/E ratio of 39.73, a PEG ratio of 1.31 and a beta of 0.55. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $296.65.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.79%. Cencora’s payout ratio is presently 31.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.